IBSA has had an official presence in the US since 2018, when it inaugurated its subsidiary IBSA Pharma Inc. Since then, the company has steadily strengthened its presence and expanded its product portfolio in the US market. In addition to IBSA Pharma Inc, the IBSA family in the US has now been joined by Yaral Pharma Inc, the generics arm of IBSA USA.
Guided by the same values, expertise and long-standing experience as IBSA, Yaral Pharma will work on a portfolio of products covering several therapeutic areas: pain and inflammation, endocrinology, reproductive medicine, osteoarticular and dermatology.
“IBSA is recognised as a world leader in the development of innovative technologies and products that improve the health and well-being of people”, said Stephen Beckman, CEO of Yaral Pharma. “We look forward to drawing on these strengths to provide high-quality products and ensure the ever-increasing well-being of patients”.
Yaral Pharma will begin marketing the first product from IBSA’s generics portfolio in January 2023.
